Literature DB >> 22495361

MSH6 mutations are frequent in hereditary nonpolyposis colorectal cancer families with normal pMSH6 expression as detected by immunohistochemistry.

Henrik Okkels1, Karen Lindorff-Larsen, Ole Thorlasius-Ussing, Mogens Vyberg, Jan Lindebjerg, Lone Sunde, Inge Bernstein, Louise Klarskov, Susanne Holck, Henrik Bygum Krarup.   

Abstract

INTRODUCTION: Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant condition accounting for 2% to 4% of all colorectal cancer cases worldwide. Families with germ line mutations in 1 of 6 mismatch repair genes are known as Lynch syndrome families. The largest number of mutations has been detected in the mismatch repair genes MLH1 and MSH2, but several mutations in MSH6 have also been demonstrated. AIM: : Whether HNPCC families are screened for mutations in mismatch repair genes often relies on their immunohistochemical profile. The aim of the present study was to evaluate this approach in Lynch families carrying mutations in MSH6.
MATERIALS AND METHODS: Results of the screening of the MSH6 gene in HNPCC families were compared with those obtained on immunohistochemical protein analysis.
RESULTS: In 56 (7%) of 815 families, at least 1 MSH6 mutation, 23 definitively pathogenic mutations and 38 missense mutations or unclassified variants, and several polymorphisms in the MSH6 gene were detected. In families carrying a pathogenic MSH6 mutation, 69.6% of 23 colon adenocarcinomas showed absence of pMSH6 in tumor tissue by immunohistochemical analysis. In 34.5%, all proteins could be detected, whereas in 34.5% pMSH6 was present and pMLH1/pPMS2 was absent.
CONCLUSIONS: If genetic screening of HNPCC families depended on immunohistochemical results, a substantial number of families harboring a pathogenic mutation in MSH6 and the vast majority of families harboring an MSH6 unclassified variant would not be detected.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495361     DOI: 10.1097/PAI.0b013e318249739b

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  9 in total

1.  Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

Authors:  Carin R Espenschied; Holly LaDuca; Shuwei Li; Rachel McFarland; Chia-Ling Gau; Heather Hampel
Journal:  J Clin Oncol       Date:  2017-05-17       Impact factor: 44.544

2.  Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences.

Authors:  Yasin Kaymaz; Cliff I Oduor; Hongbo Yu; Juliana A Otieno; John Michael Ong'echa; Ann M Moormann; Jeffrey A Bailey
Journal:  Mol Cancer Res       Date:  2017-05       Impact factor: 5.852

3.  Adrenocortical carcinoma is a lynch syndrome-associated cancer.

Authors:  Victoria M Raymond; Jessica N Everett; Larissa V Furtado; Shanna L Gustafson; Chelsy R Jungbluth; Stephen B Gruber; Gary D Hammer; Elena M Stoffel; Joel K Greenson; Thomas J Giordano; Tobias Else
Journal:  J Clin Oncol       Date:  2013-07-22       Impact factor: 44.544

4.  The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry.

Authors:  Eli Marie Grindedal; Harald Aarset; Inga Bjørnevoll; Elin Røyset; Lovise Mæhle; Astrid Stormorken; Cecilie Heramb; Heidi Medvik; Pål Møller; Wenche Sjursen
Journal:  Hered Cancer Clin Pract       Date:  2014-04-21       Impact factor: 2.857

5.  Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.

Authors:  Hellen Houlleberghs; Anne Goverde; Jarnick Lusseveld; Marleen Dekker; Marco J Bruno; Fred H Menko; Arjen R Mensenkamp; Manon C W Spaander; Anja Wagner; Robert M W Hofstra; Hein Te Riele
Journal:  PLoS Genet       Date:  2017-05-22       Impact factor: 5.917

6.  Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.

Authors:  Nayê Balzan Schneider; Tatiane Pastor; André Escremim de Paula; Maria Isabel Achatz; Ândrea Ribeiro Dos Santos; Fernanda Sales Luiz Vianna; Clévia Rosset; Manuela Pinheiro; Patricia Ashton-Prolla; Miguel Ângelo Martins Moreira; Edenir Inêz Palmero
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

7.  A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection.

Authors:  Carolina Velázquez; Enrique Lastra; Francisco Avila Cobos; Luis Abella; Virginia de la Cruz; Blanca Ascensión Hernando; Lara Hernández; Noemí Martínez; Mar Infante; Mercedes Durán
Journal:  J Transl Med       Date:  2020-06-10       Impact factor: 5.531

8.  Germline mutational profile of Chinese patients under 70 years old with colorectal cancer.

Authors:  Teng-Jia Jiang; Fang Wang; Ying-Nan Wang; Jia-Jia Hu; Pei-Rong Ding; Jun-Zhong Lin; Zhi-Zhong Pan; Gong Chen; Jian-Yong Shao; Rui-Hua Xu; Qi Zhao; Feng Wang
Journal:  Cancer Commun (Lond)       Date:  2020-09-10

9.  Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes.

Authors:  Chieh-Wen Kuo; Wuh-Liang Hwu; Yin-Hsiu Chien; Ching Hsu; Miao-Zi Hung; I-Lin Lin; Feipei Lai; Ni-Chung Lee
Journal:  Mol Genet Genomic Med       Date:  2020-08-14       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.